

2021 RRE

Agenda (Thursday) DAY 1 - Thursday, April 8th

10:00 – 10:15 am	Meeting Welcome & Updates	
	10:00 – 10:05 Welcome	Laura Thrall
	10:05 – 10:15 Meeting Goals, Deliverables	Dr. Caitlin Grzeskowiak
10:15 – 11:25 am	2021 Challenge and Overview	
	10:15 am – Presenting the challenge – Getting a therapy to a patient when they don't fit a specific category. Therapy can be approved regardless of proximal cause (analogy to fever) vs. etiological pathway. Both are possible as pathways for epilepsy. When should you do one versus the other?	Drs. Nathan Fountain & Jacqueline French
	10:35 am – High level overview of seizures vs. etiology vs. syndrome vs. group	Dr. Elaine Wirrell
	10:50 am – Patients & Family Partners Impact Panel	Allison Watson
11:25 – 11:35 am	BREAK	
11:35 – 12:10 pm	Session I: Syndromes vs. Seizures Therapeutic Approaches 11:35 am – Anti-Seizure Medication (ASM) vs. Disease Modifying (DMEM) vs. Targeted-Mechanism Epilepsy 11:50 am – Discussion	Dr. Jacqueline French
12:10 – 12:35 pm	FDA Panel	Drs. Billy Dunn & Nick Kozauer
12:35 – 1:10 pm	Lunch	
1:10 – 2:40 pm	Session II: Seizure types – Pathology and physiology Following seizure types are select examples due to time constraints, not comprehensive	Dr. Peter Crino Dr. Eleonora Aronica
	1:10 pm – Introduction to the session	
	 1:15 pm – Etiology, Pathology & Pathogenesis Infantile spasms & epileptic spasms Focal seizures, 2 years and above Generalized and bilateral Tonic-clonic seizures Tonic and Atonic seizures 	Dr. Jaideep Kapur & Dr. Michael Rogawski



4:00 – 4:10 pm	BREAK	
	3:45 pm – Infantile spasms & epileptic spasms Lecture – Epidemiology and Impact on Pathway / Treatment Response	Dr. Kelly Knupp
3:45 – 4 pm	Session IV: Epidemiology, Clinical Presentation, and treatment responsiveness Following seizure types are select examples due to time constraints, not comprehensive	
	3:15 pm – Panel Q & A	Drs. Rima Nabbout, Joseph Sullivan, Helen Cross & Sameer Zuberi
	 3:00 pm – Specific Syndrome Examples – How are they defined. LGS (symptomatology) JME (electro-clinically and genetically) Dravet (genetically) Are therapies specific to one syndrome? Are there converging pathways for the therapeutic metrics that work? 	Dr. Joseph Sullivan
	2:40 pm – Syndromes Overview – How homogeneous/generalizable are syndromes? When should syndromes respond similarly to therapies? When would we expect them to have diverse treatment response?	Dr. Rima Nabbout
2:40 – 3:30 pm	Session III: Considerations for Treating Syndromes	
	 1:45 pm – Pharmacology/Physiology of each seizure type Infantile spasms & epileptic spasms Focal seizures, 2 years and above Generalized and bilateral Tonic-clonic seizures Tonic and Atonic seizures 2:10 pm – Panel Q&A	Drs. Peter Crino, Eleonora Aronica, Jaideep Kapur & Michael Rogawski



4:10 - 5:20 pm

Session IV: Epidemiology, Clinical Presentation, and treatment responsiveness

Following seizure types are select examples due to time constraints, not comprehensive

4:10 pm - Focal seizures, 2 years and above

 Lecture – Epidemiology and Impact on Pathway / Treatment Response Dr. Daniel Friedman

4:25 pm – Generalized and focal to bilateral seizures

 Lecture – Epidemiology and Impact on Pathway / Treatment Response Dr. Robert Wechsler

4:50 pm - Panel Q & A

 Discussion – Is this seizure type sufficiently homogeneous to study by itself most of the time? What are circumstances when it wouldn't be studied by itself? Drs. Kelly Knupp, Daniel Friedman, & Robert Wechsler



2021 RRE

Agenda (Friday) DAY 2 – Friday, April 9th

8:30 – 8:40 am	Quick Refresher of Day 1	Drs. Jacqueline French & Nathan Fountain
8:40 – 9:10 am	Session IV: Epidemiology, Clinical Presentation, and treatment responsiveness Following seizure types are select examples due to time constraints, not comprehensive	
	8:40 am – Tonic and Atonic Seizures • Lecture – Epidemiology and Impact on Pathway / Treatment Response 8:55 am – Discussion – Is this seizure type sufficiently homogeneous to study by itself most of the time? What	Dr. Sudha Kessler
	are circumstances when it wouldn't be studied by itself?	Dro Kally Knynn Daniel
9:10 – 9:40 am	Wrap up - How should we study these seizure types	Drs. Kelly Knupp, Daniel Friedman, Robert Wechsler, Sudha Kessler, Dennis Dlugos
9:40 – 11:20 am	Session V: Considerations for Trial Design	
	9:40 am – Basket trial experience outside of epilepsy	Dr. Emil Kakkis
	9:55 am – Statistical considerations for basket trials	Dr. Kert Viele
	10:10 am – How to include a combination of syndromes in a basket trial that would be informative but is not a Phase III?	Dr. Dimitrios Arkilo
	What are challenges, special considerations?	
	 10:25 am – Panel Discussion – using basket trials outside of the syndrome framework. What grouping should be considered? 	Drs. Viele, Nabbout, Sullivan, Arkilo, Rogawski & Kakkis
	 10:45 am – Discussion around implications for recruitment for trials Where can syndromes be combined in trials and where can't they? What are ways to group? pragmatic/phenotypically mechanistically for impact on seizures only 	Drs. Gail Farfel, Julia Tsai, Daniel Friedman
	11:00 am – Discussions around implications for analysis & development	Drs. Kert Viele & Nathan Fountain



11:20 – 11:30 am	Break	
11:30 – 12:15 am	Wrap up and conclusions of Main Agenda	
12:15 – 1:00 pm	Lunch	
1:00 – 2:30 pm	Hot Topics / Late Breaking Topic	Drs. Auerbach, Perucca, Bergfeldt, Welty & Vossler